Methanone, with the specified name and CAS number 3031493-74-7, is a complex organic compound characterized by its intricate molecular structure, which includes multiple functional groups and stereocenters. This compound features a methanone functional group, indicating the presence of a carbonyl group (C=O) bonded to a carbon atom. The structure incorporates various heterocycles, including pyrazole and pyrrolidine rings, which contribute to its potential biological activity. The presence of an aminomethyl group suggests possible interactions with biological targets, while the chlorophenyl and indole moieties may enhance its lipophilicity and influence its pharmacokinetic properties. The stereochemistry, indicated by the (2R,4S) configuration, suggests specific spatial arrangements that can significantly affect the compound's reactivity and interactions with biological systems. Overall, this compound's unique structural features may position it as a candidate for further research in medicinal chemistry, particularly in the development of therapeutic agents.

Methanone, [(2R,4S)-4-[5-(aminomethyl)-3-methyl-1H-pyrazol-1-yl]-2-[1-[(4-chlorophenyl)methyl]-5-methyl-1H-indol-2-yl]-1-pyrrolidinyl](2-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)-

3031493-74-7: Methanone, with the specified name and CAS number 3031493-74-7, is a complex organic compound characterized by its intricate molecular structure, which includes multiple functional groups and stereocenters. This compound features a methanone functional group, indicating the presence of a carbonyl group (C=O) bonded to a carbon atom. The structure incorporates various heterocycles, including pyrazole and pyrrolidine rings, which contribute to its potential biological activity. The presence of an aminomethyl group suggests possible interactions with biological targets, while the chlorophenyl and indole moieties may enhance its lipophilicity and influence its pharmacokinetic properties. The stereochemistry, indicated by the (2R,4S) configuration, suggests specific spatial arrangements that can significantly affect the compound's reactivity and interactions with biological systems. Overall, this compound's unique structural features may position it as a candidate for further research in medicinal chemistry, particularly in the development of therapeutic agents.

NNMT-IN-3 inhibits NNMT with IC50: 1.1 nM cell-free, 0.4 μM cell-based; potential in obesity, cancer, diabetes, sarcopenia research.

CAS 3031493-74-7

Methanone, [(2R,4S)-4-[5-(aminomethyl)-3-methyl-1H-pyrazol-1-yl]-2-[1-[(4-chlorophenyl)methyl]-5-methyl-1H-indol-2-yl]-1-pyrrolidinyl](2-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)-

NNMT-IN-3

Ref: TM-T64189